168975-75-5

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-4-cyclopropylpyridine is used as a key intermediate in the synthesis of pharmaceutical drugs. Its cyclopropyl functionality allows for the modification of organic molecules, enhancing the drug's efficacy and selectivity. The halogenation of the compound adds further versatility, enabling it to participate in a wide range of chemical reactions, which is crucial for the development of new and improved medications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-chloro-4-cyclopropylpyridine serves as a valuable building block for the creation of complex organic molecules. Its unique structure and reactivity make it an ideal candidate for the synthesis of various compounds, including those with potential applications in materials science, agrochemicals, and other specialized industries.
Used in Drug Development:
2-chloro-4-cyclopropylpyridine is employed as a reagent in drug development processes. Its chemical and physical properties make it a useful component in the production of pharmaceuticals, contributing to the overall effectiveness and safety of the final drug product. By incorporating 2-chloro-4-cyclopropylpyridine into the synthesis of new drugs, researchers can explore novel therapeutic approaches and improve the treatment of various diseases and conditions.

Upstream product

• 168975-73-3 2-chloro-4-(3-hydroxypropyl)pyridine 
• 26452-80-2 2,4-dichloropyridine 
• 411235-57-9 cyclopropylboronic acid 
• 73583-37-6 2-chloro-4-bromopyridine 
• 23719-80-4 cyclopropylmagnesium bromide 
• 35717-98-7 bis(2-propyl)-p-toluenesulfonyloxymethylphosphonate 

Downstream Products

• 1620677-28-2 N-(4-cyclopropylpyridin-2-yl)-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 

Relevant academic research and scientific papers

ASK1 INHIBITING AGENTS

Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain amino-pyridine-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, and the subscript n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Chemoselective sp 2-sp3 cross-couplings: Iron-catalyzed alkyl transfer to dihaloaromatics

The chemoselective functionalization of a range of dihaloaromatics with methyl, cyclopropyl, and higher alkyl Grignard reagents via iron-catalyzed cross-coupling is described. The site selectivity of C-X (X = halogen) activation is determined by factors such as the position of the halogen on the ring, the solvent, and the nucleophile. A one-pot protocol for the chemoselective synthesis of mixed dialkyl heterocycles is achieved solely employing iron catalysis.

SYNTHESIS OF 3-(4-PYRIDINYL)-, 3-(2-CHLORO-4-PYRIDINYL)- AND 3-(2-AMINO-4-PYRIDINYL)PROPOXYMETHANEPHOSPHONIC ACID

Reaction of sodium salt of 4-(3-hydroxypropyl)pyridine (I) with diisopropyl p-toluenesulfonyloxymethanesulfonate (II) afforded diisopropyl ester of the corresponding phosphonomethyl derivative (III) together with 4-cyclopropylpyridine (IV).The ester III w